Navigation Links
Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections
Date:2/28/2011

d in a durable improvement in total CD4+ T-cell counts in five of six of the subjects analyzed.  In addition, five of the six subjects also exhibited sustained improvements in their CD4:CD8 T-cell ratio, which is an indicator of immunologic health. The ZFN-CCR5-modified cells also exhibited normal T-cell growth kinetics and trafficking and were observed to undergo selective expansion in the gut mucosa, a major reservoir of virus in the body, suggesting, as predicted, that the cells were resistant to HIV infection. These data represent the necessary first steps in the development of a "functional cure" for HIV/AIDS by providing a protected CD4+ T-cell population in these subjects that is resistant to HIV infection.

The presentation will be made at the 18th Conference on Retroviruses and Opportunistic Infections (CROI) which is being held in Boston from February 27 to March 2, 2011.  In a late-afternoon session on Wednesday, March 2, 2011, Dr. June will present further data from Sangamo's Phase 1 trials of SB-728-T and Paula Cannon, Ph.D., Associate Professor of Molecular Microbiology & Immunology at the Keck School of Medicine of the University of Southern California (USC), will present preclinical data from Sangamo's program of ZFN-modification of the CCR5 receptor in hematopoietic stem cells.  Also at CROI, Sangamo's collaborators at the University of Pennsylvania will describe preclinical data from a program to modify the CXCR4 gene in human CD4+ T-cells. More information about these presentations will be available later in the week.

"These data represent the beginning of a new hope for HIV therapy," said Jacob Lalezari, M.D., the Director of Quest Clinical Research, Assistant Clinical Professor of Medicine at Mount Zion Hospital, UCSF, and one of the principal investigators of the study. "This approach aims to provide a protected reservoir of HIV-resistant T-cells that are available to fight infections including the virus.  I
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
2. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
3. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
4. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
5. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
6. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
7. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
8. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
9. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
10. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
11. Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... , July 7, 2015   Decision Resources ... differences in dialysis patient management in the U.S. ... submitted by U.S. and EU5 nephrologists from approximately ... binders are the most commonly used renal medications ... iron differs considerably between the two regions.      ...
(Date:7/7/2015)... , July 7, 2015 The ... USD 1,197.7 million by 2020, growing at an estimated CAGR ... study by Grand View Research, Inc. Introduction of innovative technologies ... with growing awareness levels pertaining to the advantages of breast ... next six years. In addition, presence of untapped growth opportunities ...
(Date:7/7/2015)... , July 7, 2015 EnteroMedics Inc. ... devices that use neuroblocking technology to treat obesity, metabolic ... its previously announced public offering of 32,000,000 units. Each unit ... Series A warrant to purchase one share of common ... Investors whose purchase of units in the offering would ...
Breaking Medicine Technology:Similarities And Differences Exist When Comparing U.S. Versus EU5 Dialysis Patient Management 2Similarities And Differences Exist When Comparing U.S. Versus EU5 Dialysis Patient Management 3Breast Pumps Market To Reach $1,197.7 Million By 2020: Grand View Research, Inc. 2Breast Pumps Market To Reach $1,197.7 Million By 2020: Grand View Research, Inc. 3Breast Pumps Market To Reach $1,197.7 Million By 2020: Grand View Research, Inc. 4EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants 2EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants 3
... SAN RAFAEL, Calif. , Aug. 4 To ... companies have selected New Momentum, the leading SaaS-based anti-counterfeiting solution.  Both ... and shut down violators, their New Momentum solution will play a ... , , ...
... Aug. 4 Cytel Inc., premier provider of adaptive clinical trial ... software package for adaptive dose-finding studies based on frequentist or Bayesian methods. , ... The FDA,s recently issued adaptive trial guidelines ... level.  , , , ...
Cached Medicine Technology:Two More Global Pharmaceutical Companies Choose New Momentum to Stop Counterfeits 2Cytel Announces Compass® - The Only Professional Adaptive Trial Software Package for Bayesian or Frequentist Dose-Finding Studies 2Cytel Announces Compass® - The Only Professional Adaptive Trial Software Package for Bayesian or Frequentist Dose-Finding Studies 3
(Date:7/7/2015)... Norfolk, NE (PRWEB) , ... July 07, 2015 ... ... imaging center for MRI services, is debuting their brand new website. The website’s ... MRI technology and a wider selection of patient tools, including requesting appointments online. ...
(Date:7/7/2015)... MA (PRWEB) , ... July 07, 2015 , ... The ... AIDS Action Committee of Massachusetts , and the Multicultural AIDS Coalition ... and other men who have sex with men (MSM) and transgender women, the ...
(Date:7/7/2015)... ... 07, 2015 , ... Quadrino Law Group is pleased to announce the relocation ... 11747. The new facility is a state of the art building, located with ... the firm's CEO and founder, said, "We are pleased to service our clients from ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... advanced delivery technologies and development solutions for drugs, biologics and consumer health ... Excelimmune, Inc. to access its antibody combination therapy (ACT) technology platform. The ...
(Date:7/7/2015)... (PRWEB) , ... July 07, 2015 , ... Summer is ... proper precautions, however, so Amica Insurance is sharing some safety tips. , Jean Tapley, ... and gardening: , Leisure activities/sports, , Start slowly. Going from ...
Breaking Medicine News(10 mins):Health News:Northeast Nebraska Imaging Launches New Patient Friendly Website 2Health News:CDC Awards Fenway Health, AIDS Action, Multicultural AIDS Coalition $3.78m For ‘Getting To Zero’ HIV Prevention Partnership 2Health News:CDC Awards Fenway Health, AIDS Action, Multicultural AIDS Coalition $3.78m For ‘Getting To Zero’ HIV Prevention Partnership 3Health News:Catalent Biologics Adds New Technology Platform to Enable Antibody Combination Therapies 2Health News:Amica Insurance Has 7 Summer Safety Tips 2
... 2008 Researchers at Ben-Gurion University of the Negev ... recognition system, tested at a Washington, D.C. hospital, that ... by motioning instead of touching a screen, keyboard or ... to a just released article. , The June article," ...
... study from the Swedish medical university Karolinska Institute (KI) suggests ... impact on if adults decide to have sex with persons ... and the individual,s unique experiences have the strongest influence on ... largest in the world so far and was performed in ...
... When it comes to injury-related deaths, the gap between ... a study by researchers at the Johns Hopkins Bloomberg ... 1999 and 2005 injury-related deaths among blacks ages 15 ... The findings are published in the June, 2008, edition ...
... Microsoft technology to exceed ... and solve business problems., REDMOND, Wash., June ... customers, Microsoft Corp. today,announced the winners and finalists ... The awards honor Microsoft Registered, Microsoft Certified and,Microsoft ...
... Systemes, Newly,Introduced V6 Platform and Intercim,s Pertinence Suite Will be ... DEVCON 2008 in ... Intercim LLC, a global,leader in manufacturing and production operations ... (DS) (Nasdaq: DASTY; Euronext Paris: #13065, DSY.PA), a world,leader in ...
... June 16 BME (BioMedical Enterprises,Inc.), a privately ... memory implant technology, today announced the launch of ... internal fixation of,bone., The BOSS is an ... for,bone adhesion. Like the BME OSStaple(TM) product line, ...
Cached Medicine News:Health News:Gesture interface device developed by Ben-Gurion University of the Negev 2Health News:Racial disparities reduced in injury related mortality 2Health News:Microsoft Announces 2008 Partner of the Year Awards Finalists and Winners 2Health News:Microsoft Announces 2008 Partner of the Year Awards Finalists and Winners 3Health News:Microsoft Announces 2008 Partner of the Year Awards Finalists and Winners 4Health News:Microsoft Announces 2008 Partner of the Year Awards Finalists and Winners 5Health News:Microsoft Announces 2008 Partner of the Year Awards Finalists and Winners 6Health News:Microsoft Announces 2008 Partner of the Year Awards Finalists and Winners 7Health News:Intercim and Dassault Systemes Sign Memorandum of Understanding 2Health News:Intercim and Dassault Systemes Sign Memorandum of Understanding 3Health News:BME (BioMedical Enterprises, Inc.) Announces U.S. Launch of the Barbed OSStaple(TM) (BOSS) Nitinol Implant 2
A single tube that performs two rapid tests for E. coli from culture. ColiScreen™ combines both the indole test with the glucuronidase test to increase the specificity....
Legionella provides rapid, accurate results that aid in the presumptive diagnosis of Legionella infection (Legionnaires' Disease)....
... The Trinity Biotech Captia™ ... Assay (ELISA) is intended for ... antibodies (IgG and IgM) to ... in serum from patients with ...
The GoodKnight® 425 Bi-Level® device is suitable for travel and includes features such as automatic altitude compensation, optional cigarette lighter adapter and portable battery pack...
Medicine Products: